Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S8-S16 , April 2003

Achieving Low Target Pressures With Today's Glaucoma Medications

  • Louis Cantor, MD

      Affiliations

    • Corresponding Author InformationReprint address: Louis Cantor, MD, Department of Ophthalmology, Indiana University School of Medicine, 702 Rotary Circle, Indianapolis, Indiana 46202, USA

References 

  1. The Advanced Glaucoma Intervention Study (AGIS) . 9. Comparison of glaucoma outcomes in black and white patients within treatment groups. Am J Ophthalmol. 2001;132:311–320
  2. The Advanced Glaucoma Intervention Study (AGIS) . 7. The relationship between control of intraocular pressure and visual field deterioration. The AGIS Investigators. Am J Ophthalmol. 2000;130:429–440
  3. The Advanced Glaucoma Intervention Study (AGIS) . 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998;105:1146–1164
  4. Acheampong AA, Small D, Baumgarten V, et al.  Formulation effects on ocular absorption of brimonidine in rabbit eyes. J Ocul Pharmacol Ther. 2002;18:325–337
  5. Alm A, Camras CB, Watson PG. Phase III latanoprost studies in Scandinavia, the United Kingdom and the United States. Surv Ophthalmol. 1997;41(Suppl 2):S105–S110
  6. Asrani S, Zeimer R, Wilensky J, et al.  Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma. 2000;9:134–142
  7. Blackwell B. Drug therapy (patient compliance). N Engl J Med. 1973;289:249–252
  8. Bloch S, Rosenthal AR, Friedman L, Caldarolla P. Patient compliance in glaucoma. Br J Ophthalmol. 1977;61:531–534
  9. Brandt JD, Wittpenn JR, Katz LJ, et al.  Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991;112:297–301
  10. Brubaker RF. Targeting outflow facility in glaucoma management. Surv Ophthalmol. 2003;48(Suppl 1):S17–S20
  11. Brubaker RF. Mechanism of action of bimatoprost (Lumigan). Surv Ophthalmol. 2001;45(Suppl 4):S347–S351
  12. Camras CB, Alm A, Watson P, Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after. 1996;1(year of treatment in 198 patients. Latanoprost Study Groups. Ophthalmology 103):1916–1924
  13. Cantor L. Rating the efficacy, safety and tolerability of topical glaucoma medications. Rev Ophthalmol. 2001;9:14–21
  14. Cantor LB. The evolving pharmacotherapeutic profile of brimonidine, an alpha 2- adrenergic agonist, after four years of continuous use. Expert Opin Pharmacother. 2000;1:815–834
  15. Carlsen J, Durcan J, Zabriskie N, et al.  Nephrolithiasis with dorzolamide. Arch Ophthalmol. 1999;117:1087–1088
  16. Chandler PA. Progress in the treatment of glaucoma in my lifetime. Surv Ophthalmol. 1977;21:412–428
  17. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology. 1998;105:1952–1959
  18. DuBiner H, Cooke D, Dirks M. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure (a 30-day comparison with latanoprost). Surv Ophthalmol. 2001;45(Suppl 4):S353–S360
  19. Easthope SE, Perry CM. Topical bimatoprost (a review of its use in open-angle glaucoma and ocular hypertension). Drugs Aging. 2002;19:231–248
  20. Eisenberg D, Toris CB, Camras CB. Bimatoprost and travoprost (a review of recent studies of two new glaucoma drugs). Surv Ophthalmol(Suppl. 2002;1):S105–S115
  21. Epstein R, Brown SV, Dennis RF, Konowal-Allen A. Combination of systemic acetazolamide and topical dorzolamide. Ophthalmology. 1998;105:1581–1582
  22. Gandolfi S, Simmons ST, Sturm R, et al.  Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther. 2001;18:110–121
  23. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol. 2003;48(Suppl 1):S3–S7
  24. Gurwitz JH, Glynn RJ, Monane M, et al.  Treatment for glaucoma (adherence by the elderly). Am J Public Health. 1993;83:711–716
  25. Hedman K, Alm A. A pooled-data analysis of three randomized, double-masked, six-month clinical studies comparing the intraocular pressure reducing effect of latanoprost and timolol. Eur J Ophthalmol. 2000;10:95–104
  26. Higginbotham EJ, Schuman JS, Goldberg I, et al.  One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension. Arch Ophthalmol. 2002;120:1286–1293
  27. Kass MA, Heuer DK, Higginbotham EJ. The Ocular Hypertension Treatment Study (a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma). Arch Ophthalmol. 2002;120:701–713
  28. Katz LJ. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension. J Glaucoma. 2002;11:119–126
  29. Katz LJ. Brimonidine tartrate 0.2% twice daily vs timolol 0.5% twice daily (1-year results in glaucoma patients). Brimonidine Study Group. Am J Ophthalmol. 1999;127:20–26
  30. Kolker AE. Frequency of contraindications to topical beta-blockers in a glaucoma population. Invest Ophthalmol Vis Sci. 1999;40(Suppl):S514; [abstract]
  31. Konowal A, Morrison JC, Brown SV, et al.  Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403–406
  32. Lass JH, Khosrof SA, Laurence JK, et al.  A double-masked, randomized, 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Dorzolamide Corneal Effects Study Group. Arch Ophthalmol. 1998;116:1003–1010
  33. Lee DA, Gornbein JA. Effectiveness and safety of brimonidine as adjunctive therapy for patients with elevated intraocular pressure in a large, open-label community trial. J Glaucoma. 2001;10:220–226
  34. Lee ME. Beta adrenergic blocking agents for open-angle glaucoma. J Am Optom Assoc. 1988;59:567–571
  35. Lin LL, Galin MA, Obstbaum SA, Katz I. Longterm timolol therapy. Surv Ophthalmol. 1979;23:377–380
  36. MacKean JM, Elkington AR. Compliance with treatment of patients with chronic open-angle glaucoma. Br J Ophthalmol. 1983;67:46–49
  37. Netland PA, Landry T, Sullivan EK, et al.  Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2001;132:472–484
  38. Neufeld AH, Bartels SP, Liu JH. Laboratory and clinical studies on the mechanism of action of timolol. Surv Ophthalmol. 1983;28(Suppl):286–292
  39. Noecker R, Dirks M, Choplin N. A six-month randomized clinical trial comparing the IOP lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. The Bimatoprost/Latanoprost Study Group. Am J Ophthalmol. 2003;135:55–63
  40. Nuzzi R, Finazzo C, Cerruti A. Adverse effects of topical antiglaucomatous medications on the conjunctiva and the lachrymal (Brit. Engl) response. Int Ophthalmol. 1998;22:31–35
  41. Olateju SO, Ajayi AA. The lack of efficacy of topical beta-blockers, timolol and betaxolol on intraocular pressure in Nigerian healthy volunteers. Eye. 1999;13:758–763
  42. Orzalesi N, Rossetti L, Invernizzi T, et al.  Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566–2573
  43. Peak AS, Sutton BM. Systemic adverse effects associated with topically applied latanoprost. Ann Pharmacother. 1998;32:504–505
  44. Rosenberg LF, Krupin T, Tang LQ. Combination of systemic acetazolamide and topical dorzolamide in reducing intraocular pressure and aqueous humor formation. Ophthalmology. 1998;105:88–92
  45. Rusk C, Sharpe E, Laurence J, et al.  Comparison of the efficacy and safety of 2% dorzolamide and 0.5% betaxolol in the treatment of elevated intraocular pressure. Dorzolamide Comparison Study Group. Clin Ther. 1998;20:454–466
  46. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups. 2000;1(and 2. Ophthalmology 107):1171–1177
  47. Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. J Amer Acad Ophthalmol. 2000;107:1171–1177
  48. Schuman JS. Antiglaucoma medications (a review of safety and tolerability issues related to their use). Clin Ther. 2000;22:167–208
  49. Schuman JS, Horwitz B, Choplin NT, et al.  A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group. Arch Ophthalmol. 1997;115:847–852
  50. Shaffer RN. The centennial history of glaucoma (1896–1996). American Academy of Ophthalmology. Ophthalmology. 1996;103:S40–S50
  51. Sharif NA, Davis TL, Williams GW. AL-5848 ([3H] 9beta-(+)-Fluprostenol). Carboxylic acid of travoprost (AL-. 1999;6221),(a novel FP prostaglandin to study the pharmacology and autoradiographic localization of the FP receptor. J Pharm Pharmacol 51):685–694 [3H]
  52. Sherwood M, Brandt J. Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure. Surv Ophthalmol. 2001;45(Suppl 4):S361–S368
  53. Singh K, Spaeth G, Zimmerman T, Minckler D. Target pressure—glaucomatologists holey grail. Ophthalmology. 2000;107:629–630
  54. Sommer A, Tielsch JM, Katz J, et al.  Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans. The Baltimore Eye Survey. Arch Ophthalmol. 1991;109:1090–1095
  55. Strahlman E, Tipping R, Vogel R. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol. International Dorzolamide Study Group. Arch Ophthalmol. 1995;113:1009–1016
  56. Tielsch JM, Sommer A, Witt K, et al.  Blindness and visual impairment in an American urban population. The Baltimore Eye Survey. Arch Ophthalmol. 1990;108:286–290
  57. Toris CB, Camras CB, Yablonski ME, Brubaker RF. Effects of exogenous prostaglandins on aqueous humor dynamics and blood- aqueous barrier function. Surv Ophthalmol. 1997;41(Suppl 2):S69–S75
  58. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514–1517
  59. Van Buskirk EM, Fraunfelder FT. Ocular beta-blockers and systemic effects. Am J Ophthalmol. 1984;98:623–624
  60. Walters T, Shapiro A, Chapin M. A comparison of the efficacy, safety, and quality of life of brimonidine with latanoprost vs timolol with latanoprost. Invest Ophthalmol Vis Sci. 2000;41:S514
  61. Watson P, Stjernschantz J. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. The Latanoprost Study Group. Ophthalmology. 1996;103:126–137
  62. Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001;119:300–301
  63. Wheeler LA, Gil DW, WoldeMussie E. Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma. Surv Ophthalmol. 2001;45(Suppl 3):S290–S294 discussion S295–6
  64. WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension. Invest Ophthalmol Vis Sci. 2001;42:2849–2855

PII: S0039-6257(03)00009-2

doi: 10.1016/S0039-6257(03)00009-2

Survey of Ophthalmology
Volume 48, Issue 2, Supplement , Pages S8-S16 , April 2003

Article Tools

* Image Usage & Resolution